- Home
- RLYB vs OM Comparison
RLYB vs OM Comparison
Compare RLYB & OM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLYB | OM |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.3M | 74.5M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RLYB | OM |
|---|---|---|
| Price | $15.82 | $4.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.33 |
| AVG Volume (30 Days) | 37.4K | ★ 312.8K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $858,000.00 | ★ $119,476,000.00 |
| Revenue This Year | N/A | $9.29 |
| Revenue Next Year | N/A | $10.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.00 | 5.09 |
| 52 Week Low | $0.39 | $3.00 |
| 52 Week High | $17.57 | $21.36 |
Technical Indicators
Market Signals| Indicator | RLYB | OM |
|---|---|---|
| Relative Strength Index (RSI) | 57.94 | 52.68 |
| Support Level | $15.59 | $4.04 |
| Resistance Level | $17.57 | $5.05 |
| Average True Range (ATR) | 0.43 | 0.52 |
| MACD | -0.15 | 0.01 |
| Stochastic Oscillator | 24.73 | 47.06 |
Price Performance
Historical ComparisonAbout RLYB Rallybio Corporation
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
About OM Outset Medical Inc.
Outset Medical Inc is a medical technology company pioneering a technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.